Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Following a series of investor conference presentations in September, the stock has experienced recent volatility and downward pressure, with no immediate short-term catalysts identified for the next two weeks.
Jade Biosciences management presented its clinical strategy and pipeline updates at the Stifel Virtual Immunology and Inflammation Forum. While the presentation highlighted progress for lead candidate JADE101, the stock declined following the event, reflecting broader market sentiment and investor digestion of the company's long-term clinical roadmap.
Investing.com